Earlier this week, Pfizer’s CEO Ian
Read spoke about maybe splitting the company into two. Pfizer trades below 90% of its peers on a P/E
basis. For example, Bristol-Myers Squibb has a P/E of 30; Merck has a P/E of
about 20. The theory is that by
splitting the company into two separate entities, they will be able to unlock
more shareholder value.
Pfizer’s market capitalization is
roughly $200 Billion. The general
consensus is that there is at least another $35-$40 Billion more to go, making
Pfizer’s market cap around $240 Billion.
In some respects splitting the
company up maybe good. Figure that two
separate entities go up 20% a piece.
Now, the original shareholder of Pfizer, which now has both entities, is
up 20% on two separate companies. This
is what is referred to as unlocking
shareholder value. Maybe the company
is too big and would be better run as separate parts.
Consider that Altria Group (MO) also
known as Phillip Morris USA spun off multiple monster companies. They spun off Kraft foods (KFT) and Phillip
Morris International (PM). Kraft has
recently split into two companies and is now Kraft Foods Group (KRFT) and
Mondelez International (MDLZ). So if you
were an original shareholder of MO, look what you would have gotten just for
being an original shareholder! You would
have a piece of all of this!
The question is: Is it best for the shareholders of Pfizer if
the company breaks into two where the shareholders will automatically get
shares of the other. Perhaps running two
smaller entities will allow for more profitability and more shareholder
value. I am a shareholder and I would
love to see this happen!